Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Onco
Special Issues
Progress in Vaccination against Cancer - 2023 (PIVAC-23)
share announcement

Progress in Vaccination against Cancer - 2023 (PIVAC-23)

A special issue of Onco (ISSN 2673-7523).

Deadline for manuscript submissions: closed (15 April 2024) | Viewed by 4818

Special Issue Editors

Dr. Constantin N. Baxevanis

E-Mail Website
Guest Editor
Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, 171 Alexandras Av., 11522 Athens, Greece
Interests: cancer immunology; cancer immunotherapy; biomarkers; precision oncology; immune resistance; cancer vaccines; immune escape; immune checkpoint inhibitors
Special Issues, Collections and Topics in MDPI journals
Dr. Sotirios P. Fortis

E-Mail Website
Guest Editor
Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 11522 Athens, Greece
Interests: Immune genes in tumor microenvironment; tumor antigen-specific T-cell receptor frequencies in tumor microenvironment; targeted therapies for cancer; biomarkers
Special Issues, Collections and Topics in MDPI journals
Dr. Maria Goulielmaki

E-Mail Website
Guest Editor
Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, Athens, Greece
Interests: cancer biomarkers; regulation of adaptive antitumor immunity; immune resistance mechanisms; Immune-based therapies for cancer; cancer stem cells
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are delighted to invite you to the next PIVAC meeting, entitled “The 23rd International Conference on Progress in Vaccination Against Cancer” (PIVAC-23), which will be held from 28th to 30th September 2023 at the Saint Savas Cancer Hospital, 171 Alexandras avenue, Athens, Greece. PIVAC-23 aims to connect scientists working in translational and clinical cancer research for three days of presentations on the most recent advances in the following fields: (i) immunotherapies (cellular, immune checkpoint blockade, vaccines); (ii) innate immunity and tumor control; (iii) host–tumor interactions in the tumor microenvironment; (iv) in vitro and in vivo models for cancer immunotherapies; (v) combinational cancer therapy approaches; and (vi) prognostic and predictive biomarkers in tumors and immune cells.

The website of PIVAC 23 is https://scep.gr/en/events/event/pivac2023/

You are cordially invited to submit your unpublished original work attending to recent advances in all aspects of computational methods related to cancer research for the following topics:

  1. cancer biomarkers for prognosis and prediction
  2. understanding TCR specificity and cross-reactivity for predicting epitope immunogenicity
  3. the tumor microenvironment and regulation of antitumor immunity
  4. immunotherapies and immune resistance
  5. cancer immunotherapies

Dr. Constantin N. Baxevanis
Dr. Sotirios P. Fortis
Dr. Maria Goulielmaki
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Onco is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer immunotherapy
  • cancer vaccines
  • immune resistance
  • tumor microenvironment
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

14 pages, 2368 KiB  
Review
Can Tumour Antigens Act as Biomarkers for the Early Detection of Non-Small Cell Lung Cancer?
by Eithar Mohamed, Daniel Fletcher, Simon Hart and Barbara-ann Guinn
Onco 2024, 4(2), 87-100; https://doi.org/10.3390/onco4020008 - 31 May 2024
Viewed by 1051
Abstract
Lung cancer (LC) is one of the leading causes of cancer-related deaths. Pulmonary nodules are one of the risk factors, and their discovery rate has been increasing due to enhanced performance of chest CT scans, but more than 90% are non-malignant, causing unnecessary [...] Read more.
Lung cancer (LC) is one of the leading causes of cancer-related deaths. Pulmonary nodules are one of the risk factors, and their discovery rate has been increasing due to enhanced performance of chest CT scans, but more than 90% are non-malignant, causing unnecessary stress to patients and costs to healthcare providers. Early diagnosis of LC is associated with a 5-year survival rate of up to 75% following surgical resection, but LC is often diagnosed late due to a lack of symptoms and poor 5-year survival rates as low as 10%. The cost of LC diagnosis is high, with 40% of it associated with benign lesions, which are difficult to differentiate from malignant lesions. Tumour-associated antigens (TAAs) may provide one way in which LC could be diagnosed early using minimally-invasive techniques, under their association with immune responses and specificity for disease. Here we discuss the potential of cancer-testis antigens (CTAs) to act as non-invasive biomarkers for the early detection of non-small cell lung cancer. Full article
(This article belongs to the Special Issue Progress in Vaccination against Cancer - 2023 (PIVAC-23))
►▼ Show Figures

Graphical abstract

10 pages, 612 KiB  
Review
Dendritic Cell Immunotherapy for Ovarian Cancer: An Overview of Our Achievements
by Jiřina Bartůňková
Onco 2024, 4(1), 46-55; https://doi.org/10.3390/onco4010004 - 21 Mar 2024
Viewed by 1778
Abstract
Epithelial ovarian carcinoma (EOC) is the fifth leading cause of cancer-related death in women, largely reflecting the early dissemination of this malignant disease to the peritoneum. Due to its immunological features, EOC has poor response to immune checkpoint inhibitors (ICIs), including a limited [...] Read more.
Epithelial ovarian carcinoma (EOC) is the fifth leading cause of cancer-related death in women, largely reflecting the early dissemination of this malignant disease to the peritoneum. Due to its immunological features, EOC has poor response to immune checkpoint inhibitors (ICIs), including a limited tumor mutational burden (TMB), poor infiltration by immune cells, and active immunosuppression. Thus, novel strategies are needed to overcome the frequent lack of pre-existing immunity in patients with EOC. We developed and tested an autologous dendritic cell (DC)-based vaccine (DCVAC), which has recently been shown to be safe and to significantly improve progression-free survival (PFS) in two independent randomized phase II clinical trials enrolling patients with EOC (SOV01, NCT02107937; SOV02, NCT02107950). In addition, our exploratory data analyses suggest that the clinical benefits of the DCVAC were more pronounced in patients with EOC with lower-than-median TMBs and reduced CD8+ T cell infiltration. Thus, the DC-based vaccine stands out as a promising clinical tool to jumpstart anticancer immunity in patients with immunologically “cold” EOC. Our findings underscore the need for personalized immunotherapy and the clinical relevance of potential tumor-related biomarkers within the immunotherapy field. Additional clinical trials are needed to address these strategies as well as the potential value of the TMB and immune infiltration at baseline as biomarkers for guiding the clinical management of EOC. Full article
(This article belongs to the Special Issue Progress in Vaccination against Cancer - 2023 (PIVAC-23))
►▼ Show Figures

Figure 1

Other

Jump to: Review

9 pages, 729 KiB  
Commentary
How Reliable Are Predictions of CD8+ T Cell Epitope Recognition? Lessons for Cancer
by Alexander A. Lehmann, Paul V. Lehmann and Stephen Todryk
Onco 2024, 4(2), 68-76; https://doi.org/10.3390/onco4020006 - 17 Apr 2024
Viewed by 1156
Abstract
Synthetic peptides derived from antigen sequences are essential reagents for the detection of CD8+ cytotoxic T lymphocytes (CTLs), in assays such as ELISPOT/ImmunoSpot®. Indeed, the combination of peptides and ImmunoSpot® has been widely used for immune monitoring in numerous [...] Read more.
Synthetic peptides derived from antigen sequences are essential reagents for the detection of CD8+ cytotoxic T lymphocytes (CTLs), in assays such as ELISPOT/ImmunoSpot®. Indeed, the combination of peptides and ImmunoSpot® has been widely used for immune monitoring in numerous vaccine trials. Target antigens in pathogens or cancers may be large in size and multiple in number, often seemingly necessitating in silico peptide epitope predictions using algorithms and programs for certain HLA alleles to narrow down the numbers of required peptides. In this commentary, we discuss our data in the context of immune responses to viral and cancer antigens, concluding that systematic high-throughput immune monitoring of CD8+ T cells will provide more reliable insights on the host’s response to cancer than the reliance on select CD8+ T cell epitopes, no matter whether these are in silico predicted or even if they had been empirically established. We show the feasibility of large scale, high-throughput systematic CD8+ T cell epitope testing towards this goal. Full article
(This article belongs to the Special Issue Progress in Vaccination against Cancer - 2023 (PIVAC-23))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop